23andMe Offers Jargon-Free Investor Insights Online
PremiumCompany Announcements23andMe Offers Jargon-Free Investor Insights Online
2M ago
U.K., Canada privacy watchdogs launch probe into 23andMe data breach
PremiumThe Fly
U.K., Canada privacy watchdogs launch probe into 23andMe data breach
2M ago
23andMe Launches New Genetic Report on Bipolar Disorder
PremiumPress Releases
23andMe Launches New Genetic Report on Bipolar Disorder
2M ago
23andMe announces preliminary Phase 2 safety results for 23ME-00610 at ASCO
PremiumThe Fly23andMe announces preliminary Phase 2 safety results for 23ME-00610 at ASCO
2M ago
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
PremiumPress Releases
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
2M ago
Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
PremiumPress Releases
Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
2M ago
ME Earnings this Week: How Will it Perform?
PremiumPre-EarningsME Earnings this Week: How Will it Perform?
2M ago
Petros Pharmaceuticals launches U.S. distribution of STENDRA
PremiumThe Fly
Petros Pharmaceuticals launches U.S. distribution of STENDRA
2M ago
23andMe’s Lemonaid Health collabs with Petros Pharmaceuticals
PremiumThe Fly
23andMe’s Lemonaid Health collabs with Petros Pharmaceuticals
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100